Responses
Clinical/translational cancer immunotherapy
Original research
CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy
Compose a Response to This Article
Other responses
No responses have been published for this article.